LA JOLLA, Calif., June 9 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company"), announced today
that it has retained Redington, Inc., to expand the Company's outreach and
visibility to the U.S. financial community.
With specific expertise in the biopharma industry, Redington will assist
Duska in developing and managing investor relations programs that will include
market road shows and investor meetings in principal financial centers across
America. In particular, Redington will advise Duska on its financial
communications with transactional brokers, wealth managers, high net worth
individuals and sector growth investment funds. Redington's previous clients
have included Amgen, Calgene, Elan, Celgene, Medarex and Crucell.
"Duska is advancing its drug portfolio and moving forward on the strength
of clinical achievements," noted Thomas Redington, President of Redington,
Inc. "A large part of the Company's near-term milestones have yet to be
articulated to the financial community and we feel there is ample opportunity
to develop interest among new audiences."
"Redington has advised the investor relations programs of another biotech
company that I am a Board Director of and they significantly increased
shareholder value there," stated Dr. James Kuo, Chairman and CEO of Duska. "I
am glad to be working with a financial communications group of their proven
track record," he added.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., based in La Jolla, California, is a
biotechnology company focused on the development of medical products based on
ATP (adenosine triphosphate). Duska owns or has exclusive licensing rights to
proprietary medical products that are in various stages of development for the
treatment and diagnosis of certain cardiac arrhythmias, treatment of chronic
obstructive pulmonary disorder, improvement of sperm motility, and mitigation
of the toxic effects of radiation exposure. For more information, visit
http://www.duskatherapeutics.com.
About Redington, Inc.
Redington, Inc., located in Westport, CT, is a financial communications
and investor relations firm with a specialty practice for emerging life
sciences companies. It provides a full range of communications and corporate
services, including message development, presentation structure and content,
market road shows, editorial products including executive speeches, news
releases, investor literature and annual reports, media relations,
institutional and analyst introductions, and broker relationship management.
For more information, visit http://www.redingtoninc.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended that involve
risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements. The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," or variations of such
words are intended to identify such forward-looking statements. All
statements in this release regarding the future outlook related to Duska are
forward-looking statements. The forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements. Additional
uncertainties and risks are described in Duska's most recently filed SEC
documents, such as its most recent annual report on Form 10-KSB, all quarterly
reports on Form 10-QSB and any current reports on Form 8-K filed since the
date of the last Form 10-KSB. Copies of these filings are available through
the SEC website at http://www.sec.gov. All forward-looking statements are
based upon information available to Duska on the date hereof. Duska
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, other than as required by law.
SOURCE Duska Therapeutics, Inc.
James S. Kuo, M.D., M.B.A., Chairman and CEO of Duska Therapeutics, Inc.,
+1-858-551-5700, fax, +1-858-551-5704, kuoj@duskascientific.com
